STOCK TITAN

Selecta Biosciences, Inc. - SELB STOCK NEWS

Welcome to our dedicated page for Selecta Biosciences news (Ticker: SELB), a resource for investors and traders seeking the latest updates and insights on Selecta Biosciences stock.

Selecta Biosciences, Inc. (symbol: SELB) is a clinical-stage biopharmaceutical company dedicated to enhancing the efficacy of biologic therapies by reducing unwanted immune responses. The company's innovative approach leverages its proprietary tolerogenic Synthetic Vaccine Particles (SVP™) technology, which is designed to enable a wide range of biologics, particularly for rare and serious diseases that lack effective treatment options.

Selecta's current pipeline features SVP-enabled enzyme, oncology, and gene therapies. Leading the pipeline is SEL-212, a promising candidate in Phase 2 trials targeting severe gout. SEL-212 aims to alleviate debilitating symptoms such as flares and gouty arthritis, offering much-needed relief to patients. Another noteworthy candidate is SEL-403, a combination therapy comprising SVP-Rapamycin and LMB-100, which entered Phase 1 trials in 2018 for treating malignant pleural or peritoneal mesothelioma.

In addition to enzyme and oncology therapies, Selecta is developing gene therapy product candidates designed for rare metabolic disorders. These candidates hold the potential to enable repeat dosing and long-term efficacy. The company’s research endeavors are backed by a series of collaborations and partnerships that bolster its scientific and commercial capabilities.

The company's latest news highlights significant progress in its clinical trials and partnerships. Notable developments include updates on the potential of its Descartes-08 and Descartes-15 therapies to treat myasthenia gravis and other autoimmune diseases, as well as advancements in RNA Armory® technology.

Selecta continues to focus on mitigating risks inherent in clinical trials, regulatory processes, and funding requirements. The company's strategic initiatives and forward-looking statements are guided by its commitment to addressing unmet medical needs and bringing innovative therapies to market.

Rhea-AI Summary
Cartesian Therapeutics, a clinical-stage biotechnology company (NASDAQ: RNAC), highlighted its recent progress and outlined 2024 strategic priorities across its pipeline of mRNA cell therapy product candidates. The company reported positive 12-month follow-up data from Phase 2a study of Descartes-08 in myasthenia gravis, with durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores. The company also announced the expansion of its clinical pipeline following recent IND clearance for Descartes-15, a next-generation mRNA CAR-T product candidate. Cartesian ended 2023 with approximately $118M pro forma cash and cash equivalents, expected to support planned operations into the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
none
-
Rhea-AI Summary
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) announced positive twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis (MG), a chronic autoimmune disorder. Descartes-08, an autologous anti-B-cell maturation antigen (BCMA) mRNA CAR-T, showed durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores without the need for lymphodepleting chemotherapy. The manuscript titled, 'Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell Therapy,' has been submitted for peer-review and can be accessed on the online preprint server, medRxiv. Topline data from a Phase 2b placebo-controlled study is expected in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
-
Rhea-AI Summary
Selecta Biosciences, Inc. (NASDAQ: SELB) announced a merger with Cartesian Therapeutics, Inc., creating a publicly traded company pioneering RNA cell therapy for autoimmune diseases. The merger brings a pro forma cash balance of over $110 million, including $60.25 million from private financing, supporting the development of Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy for myasthenia gravis (MG), and additional RNA cell therapy programs. The combined company is expected to have multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG in mid-2024, and initiation of studies in additional autoimmune indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.04%
Tags
Rhea-AI Summary
Selecta Biosciences has entered into an agreement with Swedish Orphan Biovitrum AB (Sobi) to transition the manufacturing and development rights of ImmTOR for SEL-212. Sobi will assume responsibility for manufacturing and commercial supply starting November 6, 2023. The Biologics License Application (BLA) submission for SEL-212 is on track for the first half of 2024. Selecta employees supporting ImmTOR manufacturing and clinical development activities for SEL-212 are expected to become Sobi employees. Selecta is eligible to receive up to $615.0 million in milestone payments and royalties on net sales of SEL-212.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.2%
Tags
none
-
Rhea-AI Summary
Selecta Biosciences reports Q2 2023 financial results and provides business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
-
Rhea-AI Summary
Selecta Biosciences reports positive Phase 3 data, plans capital prioritization initiative to extend cash runway
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags

FAQ

What does Selecta Biosciences, Inc. specialize in?

Selecta Biosciences, Inc. specializes in developing biologic therapies aimed at mitigating unwanted immune responses using their proprietary SVP™ technology.

What is SEL-212?

SEL-212 is Selecta's lead candidate in Phase 2 trials, developed to treat severe gout and alleviate symptoms such as flares and gouty arthritis.

What is the significance of SVP™ technology?

SVP™ technology is designed to enhance the efficacy of biologic therapies by reducing unwanted immune responses, enabling more effective treatments for rare and severe diseases.

What are the current projects in Selecta's pipeline?

Selecta's pipeline includes SVP-enabled enzyme, oncology, and gene therapies, with products like SEL-212 for severe gout and SEL-403 for malignant mesothelioma.

What recent achievements has Selecta Biosciences made?

Recent achievements include advancements in clinical trials for SEL-212 and SEL-403, as well as progress in developing gene therapies for rare metabolic disorders.

What partnerships does Selecta Biosciences have?

Selecta has various collaborations and partnerships that enhance its scientific research and commercial outreach, aiding in the development and delivery of its therapies.

What is SEL-403?

SEL-403 is a combination therapy of SVP-Rapamycin and LMB-100, currently in Phase 1 trials for treating malignant pleural or peritoneal mesothelioma.

How does Selecta Biosciences address risks in clinical trials?

Selecta carefully manages risks through strategic planning, maintaining regulatory compliance, securing funding, and leveraging partnerships to support its clinical trials.

What are the potential applications of Selecta's gene therapy candidates?

Selecta's gene therapy candidates are being developed for rare inborn errors of metabolism, with the potential to enable repeat dosing and long-term treatment efficacy.

What are the key developments in Selecta's latest news?

Key developments include progress in clinical trials for Descartes-08 and Descartes-15, advancements in the RNA Armory® technology, and updates on the company’s innovative therapies for autoimmune diseases.

Selecta Biosciences, Inc.

Nasdaq:SELB

SELB Rankings

SELB Stock Data

135.20M
94.00M
25.06%
47.78%
5.2%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Watertown